ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate devel ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:AerSale Corporation (ASLE) provides aftermarket commercial aircraft, engines, and parts. The Zacks Consensus Estimate for its current year earnings has been revised 44.7% downward over the last 60 days.Alimera Sciences, Inc. (ALIM) is a pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 75% downward over the last 60 days.Cadence Bank (CADE) is a banking company. The Zacks Consensus Esti ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President, U.S. Operations Conference Call Participants Alex Nowak - Craig-Hallum Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdiction ...

Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -450%. A quarter ago, it was expected that this eye drug developer would post a loss of $0.41 per share when it actually produced a loss of $0.06, delivering a surprise of 85.37%.Over the last four quarters, the company has surpass ...

Revenue Growth - Q4 2023 net revenues increased by 88% to $26.3 million compared to Q4 2022[7] - Full year 2023 net revenues rose by 49% to $80.8 million compared to 2022[8] - U.S. net revenue for Q4 2023 was $19.2 million, up 104% year-over-year[11] - International net revenue for Q4 2023 reached $7.1 million, a 54% increase from Q4 2022[7] - U.S. net revenue for 2023 increased by 66% to $56.7 million, driven by the acquisition of YUTIQ[13] - International net revenue for 2023 grew by 21% to approximately $24.0 million[8] - Net revenue for the three months ended December 2023 was $26,306,000, up 87.5% from $14,029,000 in the same period of 2022[34] Profitability - Adjusted EBITDA for Q4 2023 was $5.0 million, compared to an adjusted EBITDA loss of $(1.2) million in Q4 2022[17] - The company expects to achieve over $105 million in net revenue for 2024, with an Adjusted EBITDA margin greater than 20%[4] - Full year 2023 net loss was approximately $(20.1) million, compared to $(18.1) million in 2022[8] - Net loss applicable to common shareholders for the twelve months ended December 2023 was $21,391,000, compared to a loss of $18,107,000 in 2022, reflecting a 12.6% increase in losses[34] - Non-GAAP adjusted EBITDA for the three months ended December 2023 was $5,030,000, a significant improvement from a loss of $1,238,000 in the same period of 2022[36] Assets and Liabilities - Total current assets increased to $52,423,000 in December 2023 from $29,413,000 in December 2022, representing a 78.1% growth[31] - Total liabilities rose to $107,355,000 in December 2023 from $63,410,000 in December 2022, marking a 69.2% increase[31] - Total assets increased to $153,524,000 in December 2023 from $42,602,000 in December 2022, reflecting a 260.5% growth[31] - Cash and cash equivalents increased to $12,058,000 in December 2023 from $5,274,000 in December 2022, representing a 128.5% increase[31] Operating Expenses - Operating expenses for the twelve months ended December 2023 totaled $71,849,000, up from $57,949,000 in 2022, indicating a 24% increase[34] Gross Profit - Gross profit for the twelve months ended December 2023 reached $69,917,000, a 51.5% increase compared to $46,152,000 in 2022[34] - The company reported a gross profit margin of 86.1% for the three months ended December 2023, compared to 84.8% in the same period of 2022[34] Management Changes - The company has strengthened its management team with new key appointments[9]

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2023 financial results on March 7, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an updat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jur ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Results Conference Call October 26, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Rick Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Participants Alex Nowak - Craig-Hallum Yi Chen - H.C. Wainwright Laura Suriel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Third Quarter 2022 [2023] (sic) Financial Results and Corporate Update ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Conference Call August 10, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Participants Alexander Nowak - Craig-Hallum James Molloy - Alliance Global Partners Yi Chen - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Second Quarter 2023 Financial Results Conference Call. [O ...